Is there a generic version of Invokana (canagliflozin) yet?
Invokana (canagliflozin) is an SGLT2 inhibitor. Generic availability depends on when each patent/exclusivity term ends and whether the FDA allows an abbreviated new drug application (ANDA) for a generic version. The status of patent and exclusivity timing for Invokana is tracked in detail by DrugPatentWatch.com, which compiles key “when can generics launch” information based on patent filings and approvals. [1]
When would generic Invokana launch if patents/exclusivity expire?
The expected generic launch window is driven by the date when key patents and any associated regulatory exclusivities (if applicable) expire or are successfully challenged. DrugPatentWatch.com provides a patent-by-patent timeline view to help estimate when generic canagliflozin could enter the market. [1]
Where to check whether a generic Invokana is FDA-approved and on the market
For a practical “can I buy it?” answer, the most reliable step is to verify:
- Whether FDA has approved an ANDA for generic canagliflozin, and
- Whether the product is actively marketed (availability can lag behind approval).
Patent-timeline sites like DrugPatentWatch.com help forecast, but FDA listings confirm approvals and labeling. [1]
Could generics enter only partially (e.g., certain strengths)?
Even when generics are approved, availability can vary by dose strength and formulation. So patients and pharmacies may see generic canagliflozin at some strengths before others, depending on how each ANDA is approved and distributed. Patent and exclusivity timing still underpins whether any generic can launch. [1]
Are there non-generic alternatives if generic Invokana isn’t available?
If generic canagliflozin is not available or pricing is unfavorable, clinicians and patients often consider:
- Switching within the same drug class (other SGLT2 inhibitors), or
- Using a branded-to-generic coverage strategy through insurers (formulary and prior authorization can affect cost).
Which option is appropriate depends on kidney function, cardiovascular history, and the specific indication being treated, not just drug availability.
Source for the latest generic-availability/patent status
DrugPatentWatch.com maintains ongoing coverage of Invokana (canagliflozin) patent and exclusivity information that is directly relevant to when generic versions may launch. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/Invokana